Compare Dyne Therapeutics Inc. Common Stock (DYN) vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. (ZTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. trades at $19.97 (market cap $15.45B). The key difference: ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. is far larger — about 5.4× Dyne Therapeutics Inc. Common Stock's market cap, and ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. pays a 3.34% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| DYN | ZTO | |
|---|---|---|
Market Cap | $2.86B | $15.45B |
Volume | 3,341,579 | 1,928,522 |
Sector | Health | Industrials |
52-Week High | $26.78 | $25.88 |
52-Week Low | $14.60 | $18.59 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $2.18B | $14.06B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
ZTO Express trades at $20.67, up 1.08% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with $49.1B revenue, 19.03% net margin, and attractive valuation at P/E of 10.79. Recent Q2 2026 earnings beat expectations with 11% EPS growth, while analyst consensus remains strongly positive with 70% buy ratings.
ZTO presents compelling value with 50% upside to consensus target of $30.85, supported by pricing power and cost efficiencies. Risks include competitive pressures in China's delivery market and negative cash flow trends. The stock offers growth potential through market share gains and improved pricing environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share.
ZTO Express provides domestic and international express delivery services in China. Its network-partner model combines ZTO's sorting and trunk transportation with partners' pickup and last-mile delivery.
Read more on ZTO →
